Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer

被引:6
|
作者
Johns, Andrew C. [1 ]
Yang, Mike [2 ]
Wei, Lai [3 ]
Grogan, Madison [4 ]
Spakowicz, Daniel [3 ,4 ]
Patel, Sandipkumar H. [4 ]
Li, Mingjia [5 ]
Husain, Marium [4 ]
Kendra, Kari L. [4 ]
Otterson, Gregory A. [4 ]
Rosko, Ashley E. [6 ]
Andersen, Barbara L. [7 ]
Carbone, David P. [4 ]
Owen, Dwight H. [4 ]
Presley, Carolyn J. [4 ,8 ]
机构
[1] Ohio State Univ, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[2] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[4] Ohio State Univ, Dept Internal Med, Div Med Oncol, Comprehens Canc Ctr, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Hosp Med, Dept Internal Med, Wexner Med Ctr, Columbus, OH 43210 USA
[6] Ohio State Univ, Dept Internal Med, Div Hematol, Wexner Med Ctr, Columbus, OH 43210 USA
[7] Ohio State Univ, Dept Psychol, Columbus, OH 43210 USA
[8] Ohio State Univ, James Canc Hosp & Solove Res Inst, Comprehens Canc Ctr, 13th Floor Lincoln Tower, 1800 Cannon Dr, Columbus, OH 43210 USA
来源
ONCOLOGIST | 2023年
基金
美国国家卫生研究院;
关键词
checkpoint inhibitor; immunotherapy; toxicity; geriatrics; immune-related adverse events; CHEMOTHERAPY TOXICITY; DEPRESSION; MANAGEMENT; SURVIVAL;
D O I
10.1093/oncolo/oyad097
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune checkpoint inhibitor immunotherapy is revolutionizing cancer care but can lead to significant toxicity. This article describes potential risk factors for immune-related adverse events among older adults. Objectives Immune checkpoint inhibitor immunotherapy (IO) is revolutionizing cancer care but can lead to significant toxicity. This study seeks to describe potential risk factors for immune-related adverse events (irAEs) specifically among older adults. Materials and Methods This was a retrospective study at a single academic comprehensive cancer center based on chart review data abstracted by physicians. For patients aged >= 70 years, frequency, type, and grade of irAEs and their association with baseline patient demographics, comorbidities, mobility, and functional status were characterized using bivariate analysis. Based on those results, multivariable logistic regressions were constructed to model the association between these characteristics with any grade and grade 3 or higher irAEs. Results Data were analyzed for 238 patients aged >= 70 years who received IO for mostly (>= 90%) advanced cancer between 2011 and 2018. Thirty-nine percent of older adults experienced an irAE and 13% experienced one that was grade 3 or higher. In the multivariable analysis, depression was associated with an increased incidence of any grade irAE, while decreased life-space mobility was associated with an increased incidence of grade >= 3 irAEs. Conclusion Most characteristics of special interest among older adults, include fall risk, weight loss, cognitive limitations, and hearing loss, were not associated with irAEs in our study. However, decreased life-space mobility and depression are potential risk factors for IO toxicity among older adults with advanced cancer. Interventions designed to evaluate and mitigate modifiable risk factors for treatment-related toxicity are needed, and the results of this study may be useful for guiding those efforts.
引用
收藏
页码:E625 / E632
页数:8
相关论文
共 50 条
  • [31] Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
    Laura I. Yousif
    Elles M. Screever
    Daniëlle Versluis
    Joseph Pierre Aboumsallem
    Stefan Nierkens
    Olivier C. Manintveld
    Rudolf A. de Boer
    Wouter C. Meijers
    Current Oncology Reports, 2023, 25 : 753 - 763
  • [32] The association between toxicity and efficacy of immune checkpoint inhibitors in older adults with NSCLC
    Rong, Yiran
    Ramachandran, Sujith
    Bhattacharya, Kaustuv
    Yang, Yi
    Earl, Sally
    Chang, Yunhee
    Bentley, John P.
    IMMUNOTHERAPY, 2024, 16 (16-17) : 1057 - 1068
  • [33] Immune Checkpoint Inhibitors in Older Adults
    Elias, Rawad
    Morales, Joshua
    Rehman, Yasser
    Khurshid, Humera
    CURRENT ONCOLOGY REPORTS, 2016, 18 (08)
  • [34] Burdens among Caregivers of Older Adults with Advanced Cancer and Risk Factors
    Chindaprasirt, Jarin
    Limpawattana, Panita
    Pakkaratho, Pornvaree
    Wirasorn, Kosin
    Sookprasert, Aumkhae
    Kongbunkiat, Kannikar
    Sawanyawisuth, Kittisak
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (04) : 1643 - 1648
  • [35] Immune Checkpoint Inhibitors in Older Adults
    Rawad Elias
    Joshua Morales
    Yasser Rehman
    Humera Khurshid
    Current Oncology Reports, 2016, 18
  • [36] Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer
    Muir, Christopher A.
    Menzies, Alexander M.
    Clifton-Bligh, Roderick
    Tsang, Venessa H. M.
    THYROID, 2020, 30 (10) : 1458 - 1469
  • [37] Immune checkpoint inhibitor use, multimorbidity and healthcare expenditures among older adults with late-stage melanoma
    Rai, Pragya
    Shen, Chan
    Kolodney, Joanna
    Kelly, Kimberly M.
    Scott, Virginia G.
    Sambamoorthi, Usha
    IMMUNOTHERAPY, 2021, 13 (02) : 103 - 112
  • [38] Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
    Hu, Xiangxiao
    Wang, Lina
    Shang, Bin
    Wang, Junren
    Sun, Jian
    Liang, Bin
    Su, Lili
    You, Wenjie
    Jiang, Shujuan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [39] Immunotherapy of cancer in the era of checkpoint inhibitor
    Mehmi, Inderjit
    Hamid, Omid
    CLINICAL & EXPERIMENTAL METASTASIS, 2022, 39 (01) : 231 - 237
  • [40] Immunotherapy of cancer in the era of checkpoint inhibitor
    Inderjit Mehmi
    Omid Hamid
    Clinical & Experimental Metastasis, 2022, 39 : 231 - 237